CCA
DMTX

Catalyst Capital Advisors’s Dimension Therapeutics, Inc DMTX Stock Holding History

Catalyst Capital Advisors’s Portfolio DMTX Stock Details DMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-300
Closed -$3K – 698
2015
Q4 		$3K Buy
+300
New +$3.8K ﹤0.01% 506

Other funds holding DMTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Catalyst Capital Advisors's DMTX Position: Q1 2016 in Review

Catalyst Capital Advisors sold out of Dimension Therapeutics, Inc (DMTX) in Q1 2016, closing a stake of 300 shares — an estimated $3K sold.

Catalyst Capital Advisors first reported a position in DMTX in Q4 2015 and held it in 1 quarter. The position peaked at $3K in Q4 2015. 40 funds tracked by Wall St. Rank hold DMTX as of Q1 2016.

  • Catalyst Capital Advisors reported no remaining Dimension Therapeutics, Inc position as of Q1 2016 after selling out during the quarter.
  • Catalyst Capital Advisors sold 300 Dimension Therapeutics, Inc shares in Q1 2016, an estimated $3K.
  • Catalyst Capital Advisors first reported a position in Dimension Therapeutics, Inc in Q4 2015 and held it in 1 quarter.
  • Catalyst Capital Advisors's Dimension Therapeutics, Inc position peaked at $3K in Q4 2015.
  • 40 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q1 2016.

Based on Catalyst Capital Advisors's 13F filing for Q1 2016, filed 11 May 2016.